Your browser doesn't support javascript.
loading
Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer.
Mao, Pingping; Cohen, Ofir; Kowalski, Kailey J; Kusiel, Justin G; Buendia-Buendia, Jorge E; Cuoco, Michael S; Exman, Pedro; Wander, Seth A; Waks, Adrienne G; Nayar, Utthara; Chung, Jon; Freeman, Samuel; Rozenblatt-Rosen, Orit; Miller, Vincent A; Piccioni, Federica; Root, David E; Regev, Aviv; Winer, Eric P; Lin, Nancy U; Wagle, Nikhil.
Afiliação
  • Mao P; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Cohen O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Kowalski KJ; Harvard Medical School, Boston, Massachusetts.
  • Kusiel JG; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Buendia-Buendia JE; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Cuoco MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Exman P; Harvard Medical School, Boston, Massachusetts.
  • Wander SA; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Waks AG; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Nayar U; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Chung J; Harvard Medical School, Boston, Massachusetts.
  • Freeman S; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Rozenblatt-Rosen O; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Miller VA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Piccioni F; Harvard Medical School, Boston, Massachusetts.
  • Root DE; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Regev A; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Winer EP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Lin NU; Harvard Medical School, Boston, Massachusetts.
  • Wagle N; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Clin Cancer Res ; 26(22): 5974-5989, 2020 11 15.
Article em En | MEDLINE | ID: mdl-32723837
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptor Tipo 1 de Fator de Crescimento de Fibroblastos / Receptor Tipo 2 de Fator de Crescimento de Fibroblastos / Fator 3 de Crescimento de Fibroblastos Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptor Tipo 1 de Fator de Crescimento de Fibroblastos / Receptor Tipo 2 de Fator de Crescimento de Fibroblastos / Fator 3 de Crescimento de Fibroblastos Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article